A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00055250
First received: February 21, 2003
Last updated: January 24, 2007
Last verified: January 2007

February 21, 2003
January 24, 2007
January 2003
Not Provided
6-month survival
Not Provided
Complete list of historical versions of study NCT00055250 on ClinicalTrials.gov Archive Site
  • Toxicity
  • tumor response
  • PK
Not Provided
Not Provided
Not Provided
 
A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer
A Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of Gemcitabine Plus LY293111 Compared to Gemcitabine Plus Placebo in Patients With Locally Advanced or Metastatic Pancreatic Cancer

The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Pancreatic Cancer
  • Drug: Gemcitabine
  • Drug: LY293111
  • Drug: placebo
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
130
October 2005
Not Provided

Inclusion Criteria:

  • Adenocarcinoma of the pancreas that is locally advanced or metastatic and not amenable to resection with curative intent
  • Tumor that can be measured by x-ray or scan
  • Adequate organ function

Exclusion Criteria:

  • Inability to swallow capsules
  • Documented brain metastases
  • Prior chemotherapy or biological therapy for this disease
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00055250
4840, H6H-MC-JEAL
Not Provided
Not Provided
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
January 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP